Combining Aperiodic 1/f Slopes and Brain Simulation: An EEG/MEG
Proxy Marker of Excitation/Inhibition Imbalance in Alzheimer's Disease

Pablo Martínez-Cañada[a, b, *], Eduardo Perez-Valero[a, b], Jesus Minguillon[b, c], Francisco
Pelayo[a, b], Miguel A. López-Gordo[b, c], Christian Morillas[a, b]

[a] Department of Computer Engineering, Automation and Robotics, University of Granada,
Granada, Spain

[b] Research Centre for Information and Communications Technologies (CITIC), University of
Granada, Granada, Spain

[c] Department of Signal Theory, Telematics and Communications, University of Granada,
Granada, Spain

[*] Corresponding author: Pablo Martínez-Cañada (pablomc@ugr.es)

Abstract

Accumulation and interaction of amyloid-beta (Aβ) and tau proteins during progression of Alzheimer's disease (AD) are shown to tilt neuronal circuits away from balanced excitation/inhibition (E/I). Current available techniques for noninvasive interrogation of E/I in the intact human brain, e.g., magnetic resonance spectroscopy (MRS), are highly restrictive (i.e., limited spatial extent), have low temporal and spatial resolution and suffer from the limited ability to distinguish accurately between different neurotransmitters complicating its interpretation. As such, these methods alone offer an incomplete explanation of E/I. Recently, the aperiodic component of neural power spectrum, often referred to in the literature as the '1/f slope', has been described as a promising and scalable biomarker that can track disruptions in E/I potentially underlying a spectrum of clinical conditions, such as autism, schizophrenia, or epilepsy, as well as developmental E/I changes as seen in aging. Using 1/f slopes from resting-state spectral data and computational modelling we developed a new method for inferring E/I alterations in AD. We tested our method on recent freely and publicly available electroencephalography (EEG) and magnetoencephalography (MEG) datasets of patients with AD or prodromal disease and demonstrated the method's potential for uncovering regional patterns of abnormal excitatory and inhibitory parameters. Our results provide a general framework for investigating circuit-level disorders in AD and developing therapeutic interventions that aim to restore the balance between excitation and inhibition.

Keywords: Alzheimer's Disease; Excitation-Inhibition; MEG; EEG; 1/f slope; Network of Spiking Neurons.

1. Introduction

Abnormal accumulation and circuit-level interactions of amyloid-beta (Aβ) and tau proteins in the cortex are the neuropathologic hallmarks of Alzheimer's disease (AD), starting decades before the emergence of clinically measurable cognitive deficits (Busche and Hyman 2020; Harris et al. 2020; Palop and Mucke 2016). Previous findings suggest that neuronal and circuit level modes of dysfunction (i.e., hyper- and hypoexcitability) can arise from the neuronal effects mediated by AD-related proteins. Interestingly, Aβ and tau have shown to exhibit opposing effects on local circuit dynamics. There is strong evidence that Aβ plaques, as well as soluble forms of Aβ, are a key player in driving neuronal hyperexcitability in AD, which might ultimately give rise to epileptiform activity (Zott et al. 2019; Busche et al. 2015; Verret et al. 2012; Busche et al. 2008). In direct contrast to Aβ-mediated effects, tau is associated with suppression of neuronal activity (hypoexcitability) and progressive loss of connectivity (Busche et al. 2019; Green et al. 2019). Moreover, Aβ and tau may not act independently but recent evidence suggests that both pathologies have synergistic effects (Busche and Hyman 2020). During AD progression, Aβ and tau show different temporal evolution profiles (in which tau pathology is delayed), are initially deposited in different brain regions (Aβ plaques are particularly found in medial prefrontal and medial parietal regions, while tau aggregates, in the medial temporal lobe) and propagate across other cortical regions as the disease progresses (Harris et al. 2020; Busche and Hyman 2020; van der Kant, Goldstein, and Ossenkoppele 2020; Leuzy et al. 2019; Palop and Mucke 2016). Given the complexity of the competing and synergistic functional effects between AD-related proteins, disambiguating their influence on neural dynamics and identifying how they modulate circuit excitation and inhibition (E/I balance) remains a topic of intense research (Ranasinghe et al. 2022; Maestú et al. 2021; Harris et al. 2020).

Direct and indirect in-vivo measurement of E/I is especially challenging in the human brain. Current noninvasive assessments of E/I in humans are largely restricted to magnetic resonance spectroscopy (MRS) measurements of in vivo concentrations of primary excitatory (glutamate) and inhibitory (γ-aminobutyric acid, GABA) neurotransmitters (Cuypers and Marsman 2021; Rideaux 2021; Steel et al. 2020; Stanley and Raz 2018). This approach presents several methodological challenges: the relatively low signals of glutamate and GABA complicate their interpretation because of their overlap with signals from other metabolites, it has low temporal and spatial resolution, and their measurements are usually restricted to one or few brain regions. For these reasons, current MRS approaches have limited utility for tracking variations of E/I across cortical regions or behavioural states. Recently, a range of novel features derived from electroencephalography (EEG) and magnetoencephalography (MEG) recordings have been described as robust proxy makers for noninvasive real-time measurements of changes in E/I balance (Ahmad et al. 2022; Manyukhina et al. 2022; Pablo Martínez-Cañada, Noei, and Panzeri 2021; Molina et al. 2020; Gao, Peterson, and Voytek 2017). One of the most promising candidate E/I biomarkers is the exponent of the 1/f spectral power law, often referred to in the literature as the '1/f slope'. Converging evidence from neuroimaging, pharmacological, chemogenetic and computational modelling studies has linked changes in this marker to conditions related to altered E/I balance (Pani, Saba, and Fraschini 2022), such as autism (Manyukhina et al. 2022; Trakoshis et al. 2020), schizophrenia (Molina et al. 2020), epilepsy (van Heumen et al. 2021; Pani et al. 2021) and attention-deficit/hyperactivity disorder (Karalunas et al. 2022; Robertson et al. 2019). The 1/f slope has

been additionally shown to exhibit strong changes both across healthy aging (Tran et al. 2020; Voytek et al. 2015) and during early development (Chini, Pfeffer, and Hanganu-Opatz 2022; Schaworonkow and Voytek 2021), which have been associated to alterations in the relative E/I ratio.

Here, we introduce an approach that combines 1/f slopes from resting-state spectral data and simulation of a cortical microcircuit model with recurrent interactions between excitatory and inhibitory neuronal populations (P. Martínez-Cañada et al. 2021; Mazzoni et al. 2015; Mazzoni et al. 2008) for inferring E/I alterations in AD. We used our model-based inference approach to interrogate two recent publicly available datasets of EEG (Meghdadi et al. 2021) and MEG (Vaghari et al. 2022) recordings of patients with AD or Mild Cognitive Impairment (MCI). Finally, we assessed the potential of our approach for revealing the specific shifts in E/I occurring across cortical regions distinctively associated with tau and Aβ depositions at different stages of AD.

2. Materials and Methods

2.1. Participants

We used resting-state EEG and MEG data of people with AD or prodromal disease from open and publicly available datasets. The EEG dataset (Meghdadi et al. 2021) included recordings of individuals between the ages of 40-90 that were collected at four sites in the United Sates: Advanced Brain Monitoring (ABM) in Carlsbad, California; Advanced Neurobehavioral Health (ANH) in San Diego, California; Massachusetts General Hospital (MGH) in Boston, Massachusetts; and Mayo clinic (MAYO) in Rochester, Minnesota. Healthy controls were in two age groups: between 40-60 (HC2, n = 62) and between 60-90 (HC3, n = 52). Participants in the AD group (n = 26) were in the age range of 58-90. Patients were diagnosed with AD according to neurological evaluation and neuropsychological testing based on criteria developed by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (McKhann et al. 1984) and based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for Major Neurocognitive Disorder (i.e., dementia) due to Alzheimer's disease. Participants were excluded if they reported known neurological or psychiatric disorders, cardiac arrhythmias, heart failure (e.g., myocardial infarction), epilepsy, HIV+ diagnosis, bipolar disorder, or major depression (see ref. (Meghdadi et al. 2021) for more details).

MEG data was acquired from the BioFIND project (Vaghari et al. 2022), which included individuals with clinically diagnosed MCI and healthy controls pooled over a number of different projects from two sites: the MRC Cognition & Brain Sciences Unit (CBU) in Cambridge, England, and the Centre for Biomedical Technology (CTB) in Madrid, Spain. The MCI diagnosis of patients from CBU included Addenbrooke's Cognitive Examination (ACE) and ACE Revised (ACE-R), and Mini Mental State Examination (MMSE) tests as standard. Positron Emission Tomography (PET) and fluidic biomarkers were not performed to patients, although Magnetic Resonance Imaging (MRI) was used for clinical follow-up in support of the diagnosis. The MCI diagnosis of patients from CTB was determined with intermediate probability according to the National Institute on Aging-Alzheimer Association criteria (Albert

et al. 2011), i.e., given by a clinician based on clinical and cognitive tests, self- and informant-
report, and in the absence of full dementia or obvious other causes. For some patients, there
was additional biomarker evidence of atrophy from MRI or long-term follow up and
genotyping for the APOE ε4 allele. For a subset of MCI patients, additional information was
provided indicating whether or not they subsequently progressed to dementia ('probable AD')
over subsequent years, according to their managing clinician. We only used MCI patients from
this subset so that our results can be interpreted in terms of neural changes associated with
probable AD (converted) or with patients who later did not convert to a dementia diagnosis
(not converted). Additionally, and provided that age is the most important risk factor for
developing Alzheimer's Disease (Maestú et al. 2021; Harris et al. 2020), we limited our study
of the BioFIND dataset to elder individuals (older than 75 years), including n = 50 MCI patients
(n = 27 converted, n = 23 not converted) and n = 51 controls.

2.2. M/EEG preprocessing and power spectral analysis

We used the same preprocessing methods as described in the respective publications of
the MEG and EEG datasets (Meghdadi et al. 2021; Vaghari et al. 2022). Briefly, EEG and
MEG recordings were gathered during resting state with eyes closed and bandpass filtered (1-
49 Hz for EEG data and from 0.5 to 48 Hz for MEG data). Bad channels of EEG data were
detected and removed, as well as sources other than brain (e.g., eye blinks). EEG data were
then epoched into one-second non-overlapping windows at each channel. The MEG analysis
pipeline included MEG maxfiltering, epoching (two-second window), bad epoch detection,
beamforming and region-of-interest (ROI) extraction (further details can found in ref. (Vaghari
et al. 2022)).

EEG Power spectral densities (PSD) were available out of the box in the EEG dataset
(Meghdadi et al. 2021). EEG PSDs were computed using LabX EEG processing software
(Advanced Brain Monitoring Inc., Carlsbad, California). LabX employs modified periodogram
PSD estimates with a 1-second-long Kaiser window (b = 6) and 50% overlap (see ref.
(Meghdadi et al. 2021) for further details). We computed MEG PSDs of ROIs by ourselves
using a similar approach. MEG PSDs were defined by time averaging spectrograms computed
with a 1-second-long Kaiser window (b = 6) and 50% overlap. We normalised PSDs by
dividing each EEG channel's or ROI's PSD by its mean power.

We parameterized power spectra into periodic and aperiodic components using the
FOOOF algorithm (Donoghue et al. 2020) with the following configuration: frequency range
= (1, 40) Hz, maximum number of peaks = 3, peak threshold = 1, peak width limits = (2, 50)
Hz. In this study we disregarded the periodic (oscillatory) properties of spectral fittings.
Aperiodic activity is described by a $1/f^{\chi}$ distribution, with exponentially decreasing power
across increasing frequencies. When measured in the log-log space, the χ parameter, referred
to as the aperiodic component, is computed as the negative slope of the log-log power spectrum
(1/f slope). The aperiodic component is additionally parameterized with an 'offset' parameter,
which reflects a shift of power spectrum. Since power spectrum normalization modifies relative
differences in the offset of power spectrum, we did not include this parameter in our study to
avoid misinterpretation of results.

2.3. Cortical network model and computation of field potentials

The cortical network model included an excitatory and an inhibitory population of leaky integrate-and-fire (LIF) spiking neuron models that interact through recurrent connections (P. Martínez-Cañada et al. 2021; Trakoshis et al. 2020; Mazzoni et al. 2015; Brunel and Wang 2003) (Fig. 1 A). Each population received two different Poisson signals: an external input with constant-rate (v_0) that can represent sensory or cortico-cortical inputs, and a noise input that captures intracortical fluctuations of neural activity. We used the same network configuration with the same parameters as described in previous publications (P. Martínez-Cañada et al. 2021; Trakoshis et al. 2020; Cavallari, Panzeri, and Mazzoni 2014). Briefly, the network consists of 5000 conductance-based LIF neuron models, 80% of which are excitatory (i.e., they form AMPA-like excitatory synapses with other neurons) and 20% are inhibitory (forming GABA-like synapses). Neurons in the network are randomly connected with each other (connection probability = 0.2). To account for neural activity with different E/I ratios, we performed several simulations of the recurrent network model where we systematically varied the ratio between excitatory and inhibitory synaptic conductances (g_E/g_I) across the range 0.06 – 0.2 (Fig. 1 B). We additionally set $v_0 = 3$ spikes/s, a low input strength that drives the network into an spontaneous activity regime. We repeated simulations for a given value of g_E/g_I with different random initial conditions (e.g., recurrent connections of the network). All simulations were performed using NEST v2.16.0 (Linssen 2018) and parallelized in a high-performance computing server (32-core CPU and 128 GB RAM).

Field potentials cannot be directly computed from LIF neuron models because in a LIF model all transmembrane currents collapse into a single point in space and the resulting extracellular potential (and in turn, the resulting field potential) is zero. An approximation of field potentials can be calculated using variables available from simulation of the network model (e.g., synaptic currents). Here we computed an approximation of M/EEG signals as the sum of absolute values of AMPA and GABA postsynaptic currents on excitatory cells ($\sum|I_{AMPA}| + \sum|I_{GABA}|$). This simple approach was shown to perform remarkably well in predicting simulated field potentials at different spatial scales, from local field potentials (LFPs) (Mazzoni et al. 2015) to EEGs (P. Martínez-Cañada et al. 2021) and in capturing more than 90 % of variance of empirical data recorded in neocortex (Barbieri et al. 2014; Mazzoni et al. 2008).

2.4. Regression model for estimating E/I ratio and statistical tests

We computed a least-squares polynomial regression model (degree = 2) with data from the whole set of simulations of the recurrent neural network (varying g_E/g_I across the range 0.06 – 0.2 and $v_0 = 3$ spikes/s). The regression model was computed using x = 1/f slopes from simulated field potentials and y = g_E/g_I values. Estimated parameters of the regression model were used to predict changes in g_E/g_I from slopes of empirical M/EEG data. Measures of slopes and predictions of g_E/g_I followed a normal distribution and had equal variances. We determined whether there was a significant difference between two groups of measures (e.g., control vs. AD) using a two-sided t test. Significant effects between more than two groups of measures (e.g., control, MCI converted and non-converted) were tested using a one-way ANOVA test and post-hoc pairwise comparisons with Tukey HSD confidence intervals (alpha = 0.05). In all statistical tests, data were pooled over all epochs and individuals.

3. Results

3.1. Opposing E/I shifts in posterior and anterior cortical areas of patients with AD

We first investigated whether variations in spectral slopes could be related to changes in E/I using computational modelling. We performed several simulations of a LIF neural network model with interacting excitatory and inhibitory neuronal populations (P. Martínez-Cañada et al. 2021; Trakoshis et al. 2020; Mazzoni et al. 2015) (Fig. 1 A) in which we systematically varied the ratio between synaptic conductances (g_E/g_I) (Fig. 1 B). From this model, we computed the network's M/EEGs as the sum of absolute values of all synaptic currents, an approximation that has demonstrated to capture the main properties of field potentials at different spatial scales and has been validated on both simulated and real cortical data (P. Martínez-Cañada et al. 2021; Mazzoni et al. 2015; Barbieri et al. 2014; Mazzoni et al. 2008). Consistent with previous work (Trakoshis et al. 2020; Gao, Peterson, and Voytek 2017), 1/f slopes computed from simulated field potentials decreased (flatter slopes) with increasing g_E/g_I. Using the simulation data, we computed a polynomial regression model to fit the relationship between g_E/g_I and slope values ($R^2 = 0.77$, Fig. 1 B). These modelling results indicate that changes in synaptic E/I ratio are reflected by and thus could be potentially inferred from the readout of spectral slope.

Fig. 1. Changes of spectral properties in AD and E/I imbalance predictions from the recurrent network model. (A) Overview of the network model that includes recurrent connections between two types of populations: excitatory cells (E) and inhibitory cells (I). (B) 1/f slopes from model simulations as a function of the ratio between synaptic conductances (g_E/g_I) and fit of the polynomial regression model. (C) Normalized power spectrum across all individuals from the HC2, HC3 and AD groups and over all electrode locations. Dash lines correspond to spectral fits including aperiodic and periodic components. (D) Topographic representation of mean differences in g_E/g_I. (E) Predictions of changes in g_E/g_I for specific subsets of electrodes. Asterisks in (E) indicate statistically significant g_E/g_I alterations: *** p < 0.001, ** p < 0.01 and * p < 0.05, ns: not significant.

240 We next analysed EEG data from an open EEG dataset (Meghdadi et al. 2021) that
241 included resting-state EEG recordings of healthy individuals across different ages (HC2 and
242 HC3 groups) and patients with AD. Spectral recordings of AD patients displayed, as described
243 in various studies (for review, see (Maestú et al. 2021)), slower brain oscillatory activity with
244 a prominent reduction of alpha (8-12 Hz) and beta (12-30 Hz) rhythms and increased delta/theta
245 (0.5 – 8 Hz) band activity (Fig. 1 C). Additionally, we observed a flattening of power spectrum
246 in HC3 (older) individuals (Fig. 1 C), as well as smaller slopes (Supp. Fig. 1 A), compared to
247 HC2 (younger) group, which was consistent with the hypothesis of increasing neural noise in
248 healthy aging (Tran et al. 2020; Voytek et al. 2015).

249 To test whether slopes can be used to predict changes in E/I, we computed 1/f slopes of
250 patients in AD group and age-matched controls (HC3) and used the regression model to
251 produce g_E/g_I predictions from these empirical slope measures. The topographic
252 representation of changes in g_E/g_I revealed an interesting pattern in AD with opposing effects
253 suggesting a coexistence of excitation- and inhibition-dominated regions (Fig. 1 D). This is
254 consistent with Aβ and tau effects at advanced stages of the disease, in which Aβ and tau
255 pathologies are coestablished and coexist (Harris et al. 2020). The topographic pattern of
256 variations in slopes (Supp. Fig. 1 B) was qualitatively similar to the pattern of g_E/g_I. However,
257 regional variations of slopes across different electrode locations were not significant (Supp.
258 Fig. 1 C). Importantly, we found that predictions from AD patients exhibited a significant shift
259 in g_E/g_I toward excitation in prefrontal electrode locations (Fp2, $p < 0.05$, two-sided t-test,
260 Fig. 1 E) and toward inhibition in T6 ($p < 0.05$, two-sided t-test, Fig. 1 E). Differences in
261 g_E/g_I between AD patients and controls were not significant when pooling data from all
262 electrode locations ('All', Fig. 1 E), which suggests that local synaptic excitatory and inhibitory
263 drives cancelled each other out at the global network level.

266 **Supp. Fig. 1, related to Fig. 1. Shifts in 1/f slopes in aging and AD.** (A) 1/f slope values by age pooled across
267 all electrode locations and individuals. (B) Topographic representation of mean differences in slopes. (C)
268 Comparison of slopes between AD and control (HC3) groups, computed using the same subsets of electrodes as
269 shown in Fig. 1 E. Asterisks indicate statistically significant changes in slopes: *** p < 0.001, ** p < 0.01 and *
270 p < 0.05, ns: not significant.

3.3. Cortex-wide hyperexcitability in MCI patients

We examined MEG data from a different publicly available dataset, the BioFIND dataset (Vaghari et al. 2022). This dataset included resting-state MEG data of MCI patients and healthy controls. Additional labels were provided for MCI patients indicating whether they subsequently progressed to probable AD (converted) or did not convert to a dementia diagnosis (not converted). We computed average MEG power spectra and found substantial differences in spectral properties between controls ('Ctrl') and MCI patients (Fig. 2 A). Power spectrum shapes of controls and not-converted MCI patients ('MCI$_n$') largely overlapped across a broadband of low frequencies from 0.5 to 12 Hz. In contrast, the power spectrum of converted MCI patients ('MCI$_{cv}$') comparatively captured some of the defining features of AD at lower frequencies, such as attenuation of alpha rhythm and increased delta/theta power. At higher frequencies (> 25 Hz), power spectra of MCI$_n$ and MCI$_{cv}$ eventually converged and showed higher power than control spectra.

Fig. 2. Spectral changes and E/I shifts in MCI. (A) Normalized power spectrum across all individuals from the control (Ctrl), MCI$_n$ and MCI$_{cv}$ groups and over all ROIs. (B) Surface plots (lateral view) representing mean differences in g_E/g_I. (C) Predictions of g_E/g_I pooled across all ROIs ('All'), and for a subset of selected ROIs represented in the upper surface plots (R1, R2, R3 and R4). Asterisks in (C) indicate statistically significant g_E/g_I shifts: *** $p < 0.001$, ** $p < 0.01$ and * $p < 0.05$, ns: not significant.

We then computed 1/f slopes (Supp. Fig. 3) and their corresponding g_E/g_I estimates
(Fig. 2 B and C, and Supp. Fig. 2) for every one of the 38 ROIs of the parcellation used here
(described in ref. (Colclough et al. 2015)). Hyperexcitability (i.e., increased g_E/g_I) ostensibly
dominated along cortical regions in both MCI groups and agreed with clinical data of Aβ
hyperactivity in early AD (Harris et al. 2020). Consistently, slopes of MCI$_n$ and MCI$_{cv}$ were
overall reduced across ROIs (Supp. Fig. 3). The analysis of g_E/g_I predictions pooled across
all ROIs ('All', Fig. 2 C) revealed significant global differences between controls and MCI$_n$,
and between controls and MCI$_{cv}$ ($p < 0.001$ in both cases, post-hoc Tukey HSD test).
However, most g_E/g_I shifts of MCI converters with respect to controls were not significant
across individual ROIs (R1: $p \geq 0.05$, R2: $p < 0.05$, R3: $p \geq 0.05$, R4: $p \geq 0.05$, post-hoc
Tukey HSD test, Fig. 2 C), while g_E/g_I shifts of not-converted MCI patients were consistently
significant (R1: $p < 0.01$, R2: $p < 0.01$, R3: $p < 0.01$, R4: $p < 0.01$, post-hoc Tukey HSD
test). The weaker increase in local excitability of MCI converters may be linked to the presence
of inhibitory influences that may reflect a more advanced stage of the disease and the onset of
tau pathology.

Supp. Fig. 2, related to Fig. 2. Surface plots (medial view) representing mean differences in g_E/g_I.

4. Discussion

We have described a new method for inferring alteration in the E/I balance of neuronal circuits in Alzheimer's disease using EEG and MEG measures. It is based on a recent neuroimaging biomarker, the 1/f slope, which has been proposed as a robust proxy marker for noninvasive real-time interrogation of E/I imbalance in many neuropsychiatric conditions (Ahmad et al. 2022). We used a regression model to map empirical 1/f slopes onto E/I estimations obtained from computational simulations of a recurrent cortical microcircuit model of spiking neurons that has shown to capture the main properties of simulated and real field potentials (P. Martínez-Cañada et al. 2021; Trakoshis et al. 2020; Mazzoni et al. 2015). We evaluated the ability of our approach to identify potential excitation-inhibition imbalances using recordings of patients at prodromal and clinical stages from publicly available EEG (Meghdadi et al. 2021) and MEG (Vaghari et al. 2022) datasets. Collectively, our results support the hypothesis that E/I imbalance in AD is reflected by and thus could be inferred from the readout of spectral slope and demonstrate the potential of this biomarker to be used to investigate circuit dysfunction in Alzheimer's disease models. We discuss the implications and limitations of our method below.

4.1. Predictions of E/I imbalances are potentially associated with spatiotemporal progression of tau and amyloid-beta in AD pathophysiology at circuit-level

Aβ and tau dynamically modulate neuronal and circuit activity during AD progression (Maestú et al. 2021; Harris et al. 2020; Busche and Hyman 2020; Lewandowski, Maldonado Weng, and LaDu 2020; van der Kant, Goldstein, and Ossenkoppele 2020). At earlier stages, Aβ plaques accumulate and predispose neuronal circuits toward neuronal hyperexcitability (Fig. 3). Importantly, epileptic activity and enhanced seizure susceptibility are phenomena often observed in early AD (Cretin et al. 2016; Vossel et al. 2013). A key finding from the current study is consistent with these observations. We found that E/I prediction results from the cohort of patients with MCI, a prodromal state of AD (likely between early and mid stages in Fig. 3), consistently displayed a generalized pattern of hyperexcitability along cortical regions. Tau pathology, which is primarily associated with suppression of neuronal activity, by contrast, becomes evident in later stages of AD progression, at advancing disease stages (van der Kant, Goldstein, and Ossenkoppele 2020). Indeed, it has been shown that increase in tau pathology correlates much more strongly than Aβ pathology with neurodegeneration and cognitive impairment, the hallmarks of the clinical stage of AD. Tau aggregates are commonly found in the medial temporal lobe, starting in the parahippocampal gyrus, which includes the entorhinal cortex, from which they spread to limbic areas, and from there to the association areas (Busche and Hyman 2020). At advanced stages of the disease, thus, Aβ and tau pathologies coexist and interact, and their effects, in combination, can shift neuronal circuits from balanced E/I toward hyperexcitability or hypoexcitability. Our findings based on E/I estimations using EEG data from patients with AD draw remarkable potential parallels to the

spatiotemporal evolution profiles of Aβ and tau between probably occurring at mid and late stages (Fig. 3). First, topographic representation of E/I estimates revealed a coexistence of excitation- and inhibition-dominated regions. Second, we found significant patterns of hyperexcitability in prefrontal locations (regions associated with initial Aβ deposition) and of hypoexcitability in the temporal lobe (associated with initial tau accumulation). Taken together, these results show the potential of our inference method to track E/I disruptions during AD progression both spatially and over time.

Fig. 3. Schematic representation of the spatiotemporal progression of Aβ and tau biomarker levels during AD progression. As the disease progresses, Aβ and tau show different temporal evolution profiles in which Aβ plaque deposition precedes cortical tau pathology. Aβ and tau pathologies initially start in different brain regions. Aβ plaques are initially deposited in medial prefrontal and medial parietal regions, while tau aggregates first become evident in the medial temporal lobe, probably starting in the entorhinal cortex. During AD progression, Aβ and tau spread through different areas of cortex and may interact synergistically. Blue and red shaded areas indicate the areas affected by tau and Aβ pathology, respectively. This schematic plot was created based on refs. (Harris et al. 2020; Busche and Hyman 2020; van der Kant, Goldstein, and Ossenkoppele 2020; Leuzy et al. 2019).

4.2. Impact of our method to investigate brain dysfunction at the circuit level and monitor responses to drug treatments that aim to restore the balance between excitation and inhibition

A leading theory holds that many neurodevelopmental disorders, from autism to schizophrenia, and neurodegenerative diseases, such as Alzheimer's disease, are the result of an imbalance in the activity of excitatory and inhibitory neurons (Maestú et al. 2021; Harris et al. 2020; Sohal and Rubenstein 2019; Lee, Lee, and Kim 2017; Nelson and Valakh 2015; Gogolla et al. 2009). Brain dysfunction has been traditionally investigated and diagnosed entirely at the behavioural level, whereas interventions aimed to correct alterations pharmacologically focused on the molecular level. A recent viewpoint argues that the most effective scale for neuroscientific investigation and intervention could be the circuit level (Maestú et al. 2021; Harris et al. 2020; Sohal and Rubenstein 2019; Palop and Mucke 2016), which is the intermediary scale bringing the gap between molecular and genetic changes at the microscopic level and macroscopic alterations in behaviour. Our modelling approach provides a mechanistic framework linking abnormal E/I ratio at the level of circuits (where neuronal and synaptic changes mediated by AD-related proteins possibly converge) to properties of macroscopic brain signals (M/EEG). Results of this study indicate that computational modelling at the circuit level could help integrate neurophysiological aspects of AD at the micro-, meso- and macroscale. Moreover, we have shown that our inference method largely tracks directionality of expected E/I shifts during AD progression and, thus, our approach could

be used to estimate changes in excitatory and inhibitory circuit parameters in response to administration of pharmacological drugs commonly used for treatment of different clinical disorders (e.g., memantine, ketamine or lorazepam).

4.3. Novel noninvasive E/I proxy markers

Recently, a range of novel E/I biomarkers has been described that are noninvasive and applicable in humans and which can be deployed on a large scale. (Ahmad et al. 2022). These markers represent a key translational link across species and recording scales and can be applied in resting-state experiments and tasks that do not require extensive cognitive processing. They have been used to make inferences of E/I disruptions across many psychiatric and neurodevelopmental disorders, often combined with pharmacological or chemogenetic manipulations that modulate the level of inhibition and excitation (Manyukhina et al. 2022; Trakoshis et al. 2020; Molina et al. 2020), or to uncover the neural circuit basis of some key brain processes such as development (Chini, Pfeffer, and Hanganu-Opatz 2022; Schaworonkow and Voytek 2021) or aging (Tran et al. 2020; Voytek et al. 2015). Some of these novel E/I markers are aperiodic 1/f signal (Trakoshis et al. 2020; Gao, Peterson, and Voytek 2017), neuronal avalanches (Varley et al. 2020; Lombardi, Herrmann, and de Arcangelis 2017), long-range temporal correlations (LRTC) (Bruining et al. 2020), neural entropy (Yang et al. 2012; Shew et al. 2011) and microstates (Fingelkurts et al. 2004). Although each of these markers has been mapped to a different level of neural inference in the brain, they are likely intercorrelated with one another, and potentially estimate overlapping aspects of the same underlying signal at different scales. Further work would be needed to examine the relationship between neural variables measured by each biomarker and to investigate whether they can be used in combination for a more comprehensive interrogation of E/I balance. Additionally, combining these biomarkers with other imaging techniques, such as MRS and PET (Ranasinghe et al. 2022; Vaghari, Kabir, and Henson 2022), will allow us to gain a better insight into the mechanisms of E/I by leveraging the strengths of each method.

4.4. Biophysical modelling in AD research

Previous models in AD research have lumped neural populations at each brain region into neural masses (neural mass models) (Ranasinghe et al. 2022; Monteverdi et al. 2022; van Nifterick et al. 2022; Stefanovski et al. 2021; Stefanovski et al. 2019; Zimmermann et al. 2018; de Haan et al. 2017). Using neural mass models, recent studies have found a relationship between abnormal excitatory and inhibitory time-constants and spatial depositions of Aβ and tau (Ranasinghe et al. 2022; Stefanovski et al. 2019), have linked neuronal hyperactivity in preclinical AD to oscillatory slowing (van Nifterick et al. 2022; Stefanovski et al. 2019) and have developed a successful strategy to preserve network integrity during AD progression (de Haan et al. 2017). A recent work has also used neural mass models to extract information about the excitatory/inhibitory balance in single subjects and suggested that AD subjects were characterized by increased global coupling and increased inhibition (Monteverdi et al. 2022).

Neural mass models have been proven useful to explain large-scale neuronal processes and structure-function coupling at macroscopic scales. Spiking and multicompartment models rather focus on describing neural phenomena at the micro- and mesoscopic scales and allow

researchers to simulate synaptic connectivity, individual spike events and/or whole-cell
dynamics, as well as heterogeneous parameter distributions in network populations. Due to
limited computational resources and the higher level of complexity of point neuron models and
especially multicompartment models, appropriateness and interpretability of these models at
whole-brain scale has been questioned. However, these models are uniquely positioned at an
intermediary scale of biophysical description, which facilitates interpretation of the
relationship between neuronal and synaptic changes mediated by molecular and cellular
mechanisms with circuit-level dynamics and properties of field potentials. Moreover, a range
of studies have developed biophysics-based methods for computing 'proxies' of field potentials
that provide accurate approximations of extracellular signals from simulations of spiking
network models (Hagen et al. 2022; P. Martínez-Cañada et al. 2021; Hagen et al. 2018;
Mazzoni et al. 2015). Recently, large-scale network models of cortex incorporating point
neuron or multicompartment models and data-driven long-range connectivity between areas
have shown to reproduce both experimental spiking statistics and cortico-cortical interaction
patterns measured in functional MRI (Billeh et al. 2020; Schmidt et al. 2018). Spiking and
multicompartment models offer a new perspective for unifying local and large-scale accounts
of cortical dynamics and provide a promising platform for future studies of brain function and
dysfunction.

4.5. Limitations

Our findings should be considered in the context of the following limitations. Our
approach is based on a spiking network model of recurrently connected excitatory and
inhibitory neuronal populations that has been constructed to approximate circuit phenomena
with high accuracy at the local scale level (Cavallari, Panzeri, and Mazzoni 2014; Mazzoni et
al. 2011; Mazzoni et al. 2010; Mazzoni et al. 2008). However, we did not model brain structure
and function at the scale of macroscopic networks, that is, among brain regions and their long-
range cortico-cortical connections. Mean field or neural mass models (Sanz Leon et al. 2013;
Deco, Senden, and Jirsa 2012; Destexhe and Sejnowski 2009; El Boustani and Destexhe 2009),
coupled using anatomic connectivity information, have been employed to account for whole-
brain macroscopic phenomena, such as the emergence of patterns of coherent activity across
regions in the cerebral cortex and propagation of slower oscillatory rhythms. The most effective
scale for studying AD (and other clinical conditions) and for intervention remains an area of
active research (Maestú et al. 2021; Harris et al. 2020). The challenge for future research on
neural functional impairment will be to devise and implement the necessary multilevel
computational modelling approaches that can integrate local circuitry and long-range circuit
dynamics (Billeh et al. 2020; Schmidt et al. 2018; X.J. Wang 1999).

Another limitation of our approach is that the cortical circuit model in its current form
does not include some important synaptic mechanisms such as NMDA synapses. NMDA
receptors are critically involved in persistent cortical activity underlying working memory and
evidence accumulation (Murray et al. 2014; X.J. Wang 1999). Disruptions in cortical NMDA
receptor signalling have been associated with certain brain disorders, including AD (R. Wang
and Reddy 2017), and likely affect E/I balance (Molina et al. 2020; Foss-Feig et al. 2017;
Driesen et al. 2013; Fellous and Sejnowski 2003). Using our simplified model of recurrent
AMPA and GABA synaptic currents, we have demonstrated here that E/I imbalances across

cortical regions can be consistently associated to spatiotemporal evolution profiles of AD-related proteins. An interesting topic for a future study would be to extend the spiking network model to include NMDA synapses and to assess their impact on the current prediction results of E/I alterations in AD.

Finally, it is noteworthy to mention that the experimental protocols for recording the open EEG and MEG data used in this study and for recruiting participants, though they are out of our control, include additional limitations. First is the fact that the data come from different sites. Although the recording machine models were identical, there are still differences in individual devices (e.g., in their noise level). The clinical assessments followed international guidelines but the precise categorization as AD, MCI and control is likely to differ across clinicians at different sites. The tasks performed prior to resting were different and likely had different levels of fatigue, which could have contributed to noise in the data. The groups also differ in other respects, such as age and education.

5. Conclusion

A prominent view is that circuit-level effects mediated by AD-related proteins provide diagnostic and prognostic information and offer a unique framework to understand AD and develop effective therapeutic interventions. Disambiguating the complexity of Aβ and tau excitatory and inhibitory influences and their interacting effects at the synaptic and circuit scales will be a crucial next step to identify rational therapeutic targets in AD. The approach presented here, consisting of recurrent network modelling and multimodal neuroimaging data, provides a general framework for investigating circuit-level excitatory/inhibitory imbalances and could help in linking micro- and macroscopic scales of investigation in AD.

Code and data availability

Code used to compute 1/f slopes and E/I predictions, as well as code supporting the findings of this study can be found at https://github.com/pablomc88/EEG-and-MEG-Proxy-Marker-of-Excitation-Inhibition-Imbalance-in-Alzheimer-s-Disease. The EEG dataset was downloaded from Mendeley Data and is accessible via the following DOI: 10.17632/wttpypkctg.2. The MEG dataset used in this study is available on request from the Dementia Platform UK (DPUK) (https://portal.dementiasplatform.uk/Apply).

Funding

This project has received funding from the Spanish Government and European Regional Development Funds (grants PGC2018-098813-B-C31 to E.P.V., C.M. and F.P. and PID2021-128529OA-I00 to M.A.L.G.), from "Junta de Andalucía" - Operational Programme of FEDER (grant B-TIC-352-UGR20 to E.P.V., C.M. and M.A.L.G.), from "Junta de Andalucía" - Postdoctoral Fellowship Programme PAIDI 2020/21 (to P.M.C. and J.M.) and from University of Granada – "Plan Propio de Investigación" 2021/22 (Programmes P20 to P.M.C. and J.M., P1 to J.M. and P28 to M.A.L.G). The funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We thank members of the NeuroEngineering and Computing (NECo) Lab (University of Granada, Spain) for their invaluable discussions and feedback on this work.

This work was conducted using the MRC Dementias Platform UK (DPUK). DPUK is a Public Private Partnership funded by the Medical Research Council (MR/L023784/1 and MR/009076/1). For further information on this resource visit www.dementiasplatform.uk.

Author contributions

Pablo Martínez-Cañada: Conceptualization, Methodology, Formal analysis, Software, Writing - original draft, Writing - review & editing, Funding acquisition; **Eduardo Perez-Valero**: Methodology, Writing - review & editing, Funding acquisition; **Jesus Minguillon**: Methodology, Writing - review & editing, Funding acquisition; **Francisco Pelayo**: Methodology, Writing - review & editing, Funding acquisition; **Miguel A. López-Gordo**: Methodology, Writing - review & editing, Resources, Funding acquisition; **Christian Morillas**: Methodology, Writing - review & editing, Resources, Funding acquisition.

References

Ahmad, J., C. Ellis, R. Leech, B. Voytek, P. Garces, E. Jones, J. Buitelaar, E. Loth, F. P. Dos Santos, A. F. Amil, P. F. M.J Verschure, D. Murphy, and G. McAlonan. 2022. "From mechanisms to markers: novel noninvasive EEG proxy markers of the neural excitation and inhibition system in humans." *Transl Psychiatry* 12 (1): 467. https://doi.org/10.1038/s41398-022-02218-z. https://www.ncbi.nlm.nih.gov/pubmed/36344497.

Albert, M. S., S. T. DeKosky, D. Dickson, B. Dubois, H. H. Feldman, N. C. Fox, A. Gamst, D. M. Holtzman, W. J. Jagust, R. C. Petersen, P. J. Snyder, M. C. Carrillo, B. Thies, and C. H. Phelps. 2011. "The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." *Alzheimers Dement* 7 (3): 270-9. https://doi.org/10.1016/j.jalz.2011.03.008. https://www.ncbi.nlm.nih.gov/pubmed/21514249.

Barbieri, F., A. Mazzoni, N. K. Logothetis, S. Panzeri, and N. Brunel. 2014. "Stimulus dependence of local field potential spectra: experiment versus theory." *J Neurosci* 34 (44): 14589-605. https://doi.org/10.1523/JNEUROSCI.5365-13.2014. https://www.ncbi.nlm.nih.gov/pubmed/25355213.

Billeh, Y. N., B. Cai, S. L. Gratiy, K. Dai, R. Iyer, N. W. Gouwens, R. Abbasi-Asl, X. Jia, J. H. Siegle, S. R. Olsen, C. Koch, S. Mihalas, and A. Arkhipov. 2020. "Systematic Integration of Structural and Functional Data into Multi-scale Models of Mouse Primary Visual Cortex." *Neuron* 106 (3): 388-403.e18. https://doi.org/10.1016/j.neuron.2020.01.040. https://www.ncbi.nlm.nih.gov/pubmed/32142648.

Bruining, H., R. Hardstone, E. L. Juarez-Martinez, J. Sprengers, A. E. Avramiea, S. Simpraga, S. J. Houtman, S. S. Poil, E. Dallares, S. Palva, B. Oranje, J. Matias Palva, H. D. Mansvelder, and K. Linkenkaer-Hansen. 2020. "Measurement of excitation-inhibition ratio in autism spectrum disorder using critical brain dynamics." *Sci Rep* 10 (1): 9195. https://doi.org/10.1038/s41598-020-65500-4. https://www.ncbi.nlm.nih.gov/pubmed/32513931.

Brunel, N., and X. J. Wang. 2003. "What determines the frequency of fast network oscillations with irregular neural discharges? I. Synaptic dynamics and excitation-inhibition balance." *J Neurophysiol* 90 (1): 415-30. https://doi.org/10.1152/jn.01095.2002. https://www.ncbi.nlm.nih.gov/pubmed/12611969.

Busche, M. A., G. Eichhoff, H. Adelsberger, D. Abramowski, K. H. Wiederhold, C. Haass, M. Staufenbiel, A. Konnerth, and O. Garaschuk. 2008. "Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease." *Science* 321 (5896): 1686-9. https://doi.org/10.1126/science.1162844. https://www.ncbi.nlm.nih.gov/pubmed/18802001.

Busche, M. A., and B. T. Hyman. 2020. "Synergy between amyloid-β and tau in Alzheimer's disease." *Nat Neurosci* 23 (10): 1183-1193. https://doi.org/10.1038/s41593-020-0687-6. https://www.ncbi.nlm.nih.gov/pubmed/32778792.

Busche, M. A., M. Kekuš, H. Adelsberger, T. Noda, H. Förstl, I. Nelken, and A. Konnerth. 2015. "Rescue of long-range circuit dysfunction in Alzheimer's disease models." *Nat Neurosci* 18 (11): 1623-30. https://doi.org/10.1038/nn.4137. https://www.ncbi.nlm.nih.gov/pubmed/26457554.

Busche, M. A., S. Wegmann, S. Dujardin, C. Commins, J. Schiantarelli, N. Klickstein, T. V. Kamath, G. A. Carlson, I. Nelken, and B. T. Hyman. 2019. "Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo." *Nat Neurosci* 22 (1): 57-64. https://doi.org/10.1038/s41593-018-0289-8. https://www.ncbi.nlm.nih.gov/pubmed/30559471.

Cavallari, S., S. Panzeri, and A. Mazzoni. 2014. "Comparison of the dynamics of neural interactions between current-based and conductance-based integrate-and-fire recurrent networks." *Front Neural Circuits* 8: 12. https://doi.org/10.3389/fncir.2014.00012. https://www.ncbi.nlm.nih.gov/pubmed/24634645.

Chini, M., T. Pfeffer, and I. Hanganu-Opatz. 2022. "An increase of inhibition drives the developmental decorrelation of neural activity." *Elife* 11. https://doi.org/10.7554/eLife.78811. https://www.ncbi.nlm.nih.gov/pubmed/35975980.

Colclough, G. L., M. J. Brookes, S. M. Smith, and M. W. Woolrich. 2015. "A symmetric multivariate leakage correction for MEG connectomes." *Neuroimage* 117: 439-48. https://doi.org/10.1016/j.neuroimage.2015.03.071. https://www.ncbi.nlm.nih.gov/pubmed/25862259.

Cretin, B., F. Sellal, N. Philippi, O. Bousiges, L. Di Bitonto, C. Martin-Hunyadi, and F. Blanc. 2016. "Epileptic Prodromal Alzheimer's Disease, a Retrospective Study of 13 New Cases: Expanding the Spectrum of Alzheimer's Disease to an Epileptic Variant?" *J Alzheimers Dis* 52 (3): 1125-33. https://doi.org/10.3233/JAD-150096. https://www.ncbi.nlm.nih.gov/pubmed/27104892.

Cuypers, K., and A. Marsman. 2021. "Transcranial magnetic stimulation and magnetic resonance spectroscopy: Opportunities for a bimodal approach in human neuroscience." *Neuroimage* 224: 117394. https://doi.org/10.1016/j.neuroimage.2020.117394. https://www.ncbi.nlm.nih.gov/pubmed/32987106.

de Haan, W., E. C. W. van Straaten, A. A. Gouw, and C. J. Stam. 2017. "Altering neuronal excitability to preserve network connectivity in a computational model of Alzheimer's disease." *PLoS Comput Biol* 13 (9): e1005707. https://doi.org/10.1371/journal.pcbi.1005707. https://www.ncbi.nlm.nih.gov/pubmed/28938009.

Deco, G., M. Senden, and V. Jirsa. 2012. "How anatomy shapes dynamics: a semi-analytical study of the brain at rest by a simple spin model." *Front Comput Neurosci* 6: 68. https://doi.org/10.3389/fncom.2012.00068. https://www.ncbi.nlm.nih.gov/pubmed/23024632.

Destexhe, A., and T. J. Sejnowski. 2009. "The Wilson-Cowan model, 36 years later." *Biol Cybern* 101 (1): 1-2. https://doi.org/10.1007/s00422-009-0328-3. https://www.ncbi.nlm.nih.gov/pubmed/19662434.

Donoghue, T., M. Haller, E. J. Peterson, P. Varma, P. Sebastian, R. Gao, T. Noto, A. H. Lara, J. D. Wallis, R. T. Knight, A. Shestyuk, and B. Voytek. 2020. "Parameterizing neural power spectra into periodic and aperiodic components." *Nat Neurosci* 23 (12): 1655-1665. https://doi.org/10.1038/s41593-020-00744-x. https://www.ncbi.nlm.nih.gov/pubmed/33230329.

Driesen, N. R., G. McCarthy, Z. Bhagwagar, M. H. Bloch, V. D. Calhoun, D. C. D'Souza, R. Gueorguieva, G. He, H. C. Leung, R. Ramani, A. Anticevic, R. F. Suckow, P. T. Morgan, and J. H. Krystal. 2013. "The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity." *Neuropsychopharmacology* 38 (13): 2613-22. https://doi.org/10.1038/npp.2013.170. https://www.ncbi.nlm.nih.gov/pubmed/23856634.

El Boustani, S., and A. Destexhe. 2009. "A master equation formalism for macroscopic modeling of asynchronous irregular activity states." *Neural Comput* 21 (1): 46-100. https://doi.org/10.1162/neco.2009.02-08-710. https://www.ncbi.nlm.nih.gov/pubmed/19210171.

Fellous, J. M., and T. J. Sejnowski. 2003. "Regulation of persistent activity by background inhibition in an in vitro model of a cortical microcircuit." *Cereb Cortex* 13 (11): 1232-41. https://doi.org/10.1093/cercor/bhg098. https://www.ncbi.nlm.nih.gov/pubmed/14576214.

Fingelkurts, A. A., R. Kivisaari, E. Pekkonen, R. J. Ilmoniemi, and S. Kähkönen. 2004. "Local and remote functional connectivity of neocortex under the inhibition influence." *Neuroimage* 22 (3): 1390-406. https://doi.org/10.1016/j.neuroimage.2004.03.013. https://www.ncbi.nlm.nih.gov/pubmed/15219610.

Foss-Feig, J. H., B. D. Adkinson, J. L. Ji, G. Yang, V. H. Srihari, J. C. McPartland, J. H. Krystal, J. D. Murray, and A. Anticevic. 2017. "Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders." *Biol Psychiatry* 81 (10): 848-861. https://doi.org/10.1016/j.biopsych.2017.03.005. https://www.ncbi.nlm.nih.gov/pubmed/28434615.

Gao, R., E. J. Peterson, and B. Voytek. 2017. "Inferring synaptic excitation/inhibition balance from field potentials." *Neuroimage* 158: 70-78. https://doi.org/10.1016/j.neuroimage.2017.06.078. https://www.ncbi.nlm.nih.gov/pubmed/28676297.

Gogolla, N., J. J. Leblanc, K. B. Quast, T. C. Südhof, M. Fagiolini, and T. K. Hensch. 2009. "Common circuit defect of excitatory-inhibitory balance in mouse models of autism." *J Neurodev Disord* 1 (2): 172-81. https://doi.org/10.1007/s11689-009-9023-x. https://www.ncbi.nlm.nih.gov/pubmed/20664807.

Green, C., A. Sydow, S. Vogel, M. Anglada-Huguet, D. Wiedermann, E. Mandelkow, E. M. Mandelkow, and M. Hoehn. 2019. "Functional networks are impaired by elevated tau-protein but reversible in a regulatable Alzheimer's disease mouse model." *Mol Neurodegener* 14 (1): 13. https://doi.org/10.1186/s13024-019-0316-6. https://www.ncbi.nlm.nih.gov/pubmed/30917861.

Hagen, E., S. H. Magnusson, T. V. Ness, G. Halnes, P. N. Babu, C. Linssen, A. Morrison, and G. T. Einevoll. 2022. "Brain signal predictions from multi-scale networks using a linearized framework." *PLoS Comput Biol* 18 (8): e1010353. https://doi.org/10.1371/journal.pcbi.1010353. https://www.ncbi.nlm.nih.gov/pubmed/35960767.

Hagen, E., S. Næss, T. V. Ness, and G. T. Einevoll. 2018. "Multimodal Modeling of Neural Network Activity: Computing LFP, ECoG, EEG, and MEG Signals With LFPy 2.0." *Front Neuroinform* 12: 92. https://doi.org/10.3389/fninf.2018.00092. https://www.ncbi.nlm.nih.gov/pubmed/30618697.

Harris, S. S., F. Wolf, B. De Strooper, and M. A. Busche. 2020. "Tipping the Scales: Peptide-Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer's Disease." *Neuron* 107 (3): 417-435. https://doi.org/10.1016/j.neuron.2020.06.005. https://www.ncbi.nlm.nih.gov/pubmed/32579881.

Karalunas, Sarah L., Brendan D. Ostlund, Brittany R. Alperin, McKenzie Figuracion, Hanna C. Gustafsson, Erika Michiko Deming, Dan Foti, Dylan Antovich, Jason Dude, Joel Nigg, and Elinor Sullivan. 2022. "Electroencephalogram aperiodic power spectral slope can be reliably measured and predicts ADHD risk in early development." *Developmental Psychobiology* 64 (3): e22228. https://doi.org/https://doi.org/10.1002/dev.22228. https://onlinelibrary.wiley.com/doi/abs/10.1002/dev.22228.

Lee, E., J. Lee, and E. Kim. 2017. "Excitation/Inhibition Imbalance in Animal Models of Autism Spectrum Disorders." *Biol Psychiatry* 81 (10): 838-847. https://doi.org/10.1016/j.biopsych.2016.05.011. https://www.ncbi.nlm.nih.gov/pubmed/27450033.

Leuzy, A., K. Chiotis, L. Lemoine, P. G. Gillberg, O. Almkvist, E. Rodriguez-Vieitez, and A. Nordberg. 2019. "Tau PET imaging in neurodegenerative tauopathies-still a challenge." *Mol Psychiatry* 24 (8): 1112-1134. https://doi.org/10.1038/s41380-018-0342-8. https://www.ncbi.nlm.nih.gov/pubmed/30635637.

Lewandowski, C. T., J. Maldonado Weng, and M. J. LaDu. 2020. "Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How." *Neurobiol Dis* 139: 104811. https://doi.org/10.1016/j.nbd.2020.104811. https://www.ncbi.nlm.nih.gov/pubmed/32087290.

Linssen, CharlLepperød, Mikkel ElleMitchell, JessicaPronold, JariEppler, Jochen MartinKeup, ChrisitanPeyser, AlexanderKunkel, SusanneWeidel, PhilippNodem, YannickTerhorst, DennisDeepu, RajalekshmiDeger, MoritzHahne, JanSinha, AnkurAntonietti, AlbertoSchmidt, MaximilianPaz, LucianoGarrido, JesúsIppen, TammoRiquelme, LuisAlex SerenkoKühn, TobiasKitayama, ItaruMørk, HåkonSpreizer, SebastianJordan, JakobKrishnan, JeyashreeSenden, MarioHagen, EspenShusharin, AlexeyVennemo, Stine BrekkeRodarie, DimitriMorrison, AbigailGraber, SteffenSchuecker, JannisDiaz, SandraZajzon, BarnaPlesser, Hans Ekkehard. 2018. NEST 2.16.0. Zenodo.

Lombardi, F., H. J. Herrmann, and L. de Arcangelis. 2017. "Balance of excitation and inhibition determines 1/f power spectrum in neuronal networks." *Chaos* 27 (4): 047402. https://doi.org/10.1063/1.4979043. https://www.ncbi.nlm.nih.gov/pubmed/28456161.

Maestú, F., W. de Haan, M. A. Busche, and J. DeFelipe. 2021. "Neuronal excitation/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology." *Ageing Res Rev* 69: 101372. https://doi.org/10.1016/j.arr.2021.101372. https://www.ncbi.nlm.nih.gov/pubmed/34029743.

Manyukhina, V. O., A. O. Prokofyev, I. A. Galuta, D. E. Goiaeva, T. S. Obukhova, J. F. Schneiderman, D. I. Altukhov, T. A. Stroganova, and E. V. Orekhova. 2022. "Globally elevated excitation-inhibition ratio in children with autism spectrum disorder and below-average intelligence." *Mol Autism* 13 (1): 20. https://doi.org/10.1186/s13229-022-00498-2. https://www.ncbi.nlm.nih.gov/pubmed/35550191.

Martínez-Cañada, P., T. V. Ness, G. T. Einevoll, T. Fellin, and S. Panzeri. 2021. "Computation of the electroencephalogram (EEG) from network models of point neurons." *PLoS Comput Biol* 17 (4): e1008893. https://doi.org/10.1371/journal.pcbi.1008893. https://www.ncbi.nlm.nih.gov/pubmed/33798190.

Martínez-Cañada, Pablo, Shahryar Noei, and Stefano Panzeri. 2021. "Methods for inferring neural circuit interactions and neuromodulation from local field potential and electroencephalogram measures." *Brain Informatics* 8 (1): 27. https://doi.org/10.1186/s40708-021-00148-y. https://doi.org/10.1186/s40708-021-00148-y.

Mazzoni, A., N. Brunel, S. Cavallari, N. K. Logothetis, and S. Panzeri. 2011. "Cortical dynamics during naturalistic sensory stimulations: experiments and models." *J Physiol Paris* 105 (1-3): 2-15. https://doi.org/10.1016/j.jphysparis.2011.07.014. https://www.ncbi.nlm.nih.gov/pubmed/21907800.

Mazzoni, A., H. Lindén, H. Cuntz, A. Lansner, S. Panzeri, and G. T. Einevoll. 2015. "Computing the Local Field Potential (LFP) from Integrate-and-Fire Network Models." *PLoS Comput Biol* 11 (12):

e1004584.   https://doi.org/10.1371/journal.pcbi.1004584.
https://www.ncbi.nlm.nih.gov/pubmed/26657024.
Mazzoni, A., S. Panzeri, N. K. Logothetis, and N. Brunel. 2008. "Encoding of naturalistic stimuli by local
field potential spectra in networks of excitatory and inhibitory neurons." *PLoS Comput Biol* 4
(12):   e1000239.   https://doi.org/10.1371/journal.pcbi.1000239.
https://www.ncbi.nlm.nih.gov/pubmed/19079571.
Mazzoni, A., K. Whittingstall, N. Brunel, N. K. Logothetis, and S. Panzeri. 2010. "Understanding the
relationships between spike rate and delta/gamma frequency bands of LFPs and EEGs using a
local   cortical   network   model."   *Neuroimage*   52   (3):   956-72.
https://doi.org/10.1016/j.neuroimage.2009.12.040.
https://www.ncbi.nlm.nih.gov/pubmed/20026218.
McKhann, G., D. Drachman, M. Folstein, R. Katzman, D. Price, and E. M. Stadlan. 1984. "Clinical
diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the
auspices of Department of Health and Human Services Task Force on Alzheimer's Disease."
Neurology   34   (7):   939-44.   https://doi.org/10.1212/wnl.34.7.939.
https://www.ncbi.nlm.nih.gov/pubmed/6610841.
Meghdadi, A. H., M. Stevanović Karić, M. McConnell, G. Rupp, C. Richard, J. Hamilton, D. Salat, and C.
Berka. 2021. "Resting state EEG biomarkers of cognitive decline associated with Alzheimer's
disease   and   mild   cognitive   impairment."   *PLoS   One*   16   (2):   e0244180.
https://doi.org/10.1371/journal.pone.0244180.
https://www.ncbi.nlm.nih.gov/pubmed/33544703.
Molina, J. L., B. Voytek, M. L. Thomas, Y. B. Joshi, S. G. Bhakta, J. A. Talledo, N. R. Swerdlow, and G. A.
Light. 2020. "Memantine Effects on Electroencephalographic Measures of Putative
Excitatory/Inhibitory Balance in Schizophrenia." *Biol Psychiatry Cogn Neurosci Neuroimaging*
5   (6):   562-568.   https://doi.org/10.1016/j.bpsc.2020.02.004.
https://www.ncbi.nlm.nih.gov/pubmed/32340927.
Monteverdi, A., F. Palesi, A. Costa, P. Vitali, A. Pichiecchio, M. Cotta Ramusino, S. Bernini, V. Jirsa, C.
A. M. Gandini Wheeler-Kingshott, and E. D'Angelo. 2022. "Subject-specific features of
excitation/inhibition profiles in neurodegenerative diseases." *Front Aging Neurosci* 14:
868342.   https://doi.org/10.3389/fnagi.2022.868342.
https://www.ncbi.nlm.nih.gov/pubmed/35992607.
Murray, J. D., A. Anticevic, M. Gancsos, M. Ichinose, P. R. Corlett, J. H. Krystal, and X. J. Wang. 2014.
"Linking microcircuit dysfunction to cognitive impairment: effects of disinhibition associated
with schizophrenia in a cortical working memory model." *Cereb Cortex* 24 (4): 859-72.
https://doi.org/10.1093/cercor/bhs370. https://www.ncbi.nlm.nih.gov/pubmed/23203979.
Nelson, S. B., and V. Valakh. 2015. "Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism
Spectrum Disorders." *Neuron* 87 (4): 684-98. https://doi.org/10.1016/j.neuron.2015.07.033.
https://www.ncbi.nlm.nih.gov/pubmed/26291155.
Palop, J. J., and L. Mucke. 2016. "Network abnormalities and interneuron dysfunction in Alzheimer
disease." *Nat Rev Neurosci* 17 (12): 777-792. https://doi.org/10.1038/nrn.2016.141.
https://www.ncbi.nlm.nih.gov/pubmed/27829687.
Pani, S. M., M. Fraschini, M. Figorilli, L. Tamburrino, R. Ferri, and M. Puligheddu. 2021. "Sleep-related
hypermotor epilepsy and non-rapid eye movement parasomnias: Differences in the periodic
and aperiodic component of the electroencephalographic power spectra." *J Sleep Res* 30 (5):
e13339.   https://doi.org/10.1111/jsr.13339.
https://www.ncbi.nlm.nih.gov/pubmed/33769647.
Pani, S. M., L. Saba, and M. Fraschini. 2022. "Clinical applications of EEG power spectra aperiodic
component   analysis: A   mini-review."   *Clin   Neurophysiol*   143:   1-13.
https://doi.org/10.1016/j.clinph.2022.08.010.
https://www.ncbi.nlm.nih.gov/pubmed/36088797.

Ranasinghe, K. G., P. Verma, C. Cai, X. Xie, K. Kudo, X. Gao, H. Lerner, D. Mizuiri, A. Strom, L. Iaccarino, R. La Joie, B. L. Miller, M. L. Gorno-Tempini, K. P. Rankin, W. J. Jagust, K. Vossel, G. D. Rabinovici, A. Raj, and S. S. Nagarajan. 2022. "Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer's disease." *Elife* 11. https://doi.org/10.7554/eLife.77850. https://www.ncbi.nlm.nih.gov/pubmed/35616532.

Rideaux, R. 2021. "No balance between glutamate+glutamine and GABA+ in visual or motor cortices of the human brain: A magnetic resonance spectroscopy study." *Neuroimage* 237: 118191. https://doi.org/10.1016/j.neuroimage.2021.118191. https://www.ncbi.nlm.nih.gov/pubmed/34023450.

Robertson, M. M., S. Furlong, B. Voytek, T. Donoghue, C. A. Boettiger, and M. A. Sheridan. 2019. "EEG power spectral slope differs by ADHD status and stimulant medication exposure in early childhood." *J Neurophysiol* 122 (6): 2427-2437. https://doi.org/10.1152/jn.00388.2019. https://www.ncbi.nlm.nih.gov/pubmed/31619109.

Sanz Leon, P., S. A. Knock, M. M. Woodman, L. Domide, J. Mersmann, A. R. McIntosh, and V. Jirsa. 2013. "The Virtual Brain: a simulator of primate brain network dynamics." *Front Neuroinform* 7: 10. https://doi.org/10.3389/fninf.2013.00010. https://www.ncbi.nlm.nih.gov/pubmed/23781198.

Schaworonkow, N., and B. Voytek. 2021. "Longitudinal changes in aperiodic and periodic activity in electrophysiological recordings in the first seven months of life." *Dev Cogn Neurosci* 47: 100895. https://doi.org/10.1016/j.dcn.2020.100895. https://www.ncbi.nlm.nih.gov/pubmed/33316695.

Schmidt, M., R. Bakker, K. Shen, G. Bezgin, M. Diesmann, and S. J. van Albada. 2018. "A multi-scale layer-resolved spiking network model of resting-state dynamics in macaque visual cortical areas." *PLoS Comput Biol* 14 (10): e1006359. https://doi.org/10.1371/journal.pcbi.1006359. https://www.ncbi.nlm.nih.gov/pubmed/30335761.

Shew, W. L., H. Yang, S. Yu, R. Roy, and D. Plenz. 2011. "Information capacity and transmission are maximized in balanced cortical networks with neuronal avalanches." *J Neurosci* 31 (1): 55-63. https://doi.org/10.1523/JNEUROSCI.4637-10.2011. https://www.ncbi.nlm.nih.gov/pubmed/21209189.

Sohal, V. S., and J. L. R. Rubenstein. 2019. "Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders." *Mol Psychiatry* 24 (9): 1248-1257. https://doi.org/10.1038/s41380-019-0426-0. https://www.ncbi.nlm.nih.gov/pubmed/31089192.

Stanley, J. A., and N. Raz. 2018. "Functional Magnetic Resonance Spectroscopy: The "New" MRS for Cognitive Neuroscience and Psychiatry Research." *Front Psychiatry* 9: 76. https://doi.org/10.3389/fpsyt.2018.00076. https://www.ncbi.nlm.nih.gov/pubmed/29593585.

Steel, A., M. Mikkelsen, R. A. E. Edden, and C. E. Robertson. 2020. "Regional balance between glutamate+glutamine and GABA+ in the resting human brain." *Neuroimage* 220: 117112. https://doi.org/10.1016/j.neuroimage.2020.117112. https://www.ncbi.nlm.nih.gov/pubmed/32619710.

Stefanovski, L., J. M. Meier, R. K. Pai, P. Triebkorn, T. Lett, L. Martin, K. Bülau, M. Hofmann-Apitius, A. Solodkin, A. R. McIntosh, and P. Ritter. 2021. "Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain." *Front Neuroinform* 15: 630172. https://doi.org/10.3389/fninf.2021.630172. https://www.ncbi.nlm.nih.gov/pubmed/33867964.

Stefanovski, L., P. Triebkorn, A. Spiegler, M. A. Diaz-Cortes, A. Solodkin, V. Jirsa, A. R. McIntosh, P. Ritter, and Alzheimer's Disease Neuroimaging Initiative. 2019. "Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease." *Front Comput Neurosci* 13: 54.

https://doi.org/10.3389/fncom.2019.00054.
https://www.ncbi.nlm.nih.gov/pubmed/31456676.
Trakoshis, S., P. Martínez-Cañada, F. Rocchi, C. Canella, W. You, B. Chakrabarti, A. N. Ruigrok, E. T.
Bullmore, J. Suckling, M. Markicevic, V. Zerbi, S. Baron-Cohen, A. Gozzi, M. C. Lai, S. Panzeri,
M. V. Lombardo, and MRC AIMS Consortium. 2020. "Intrinsic excitation-inhibition imbalance
affects medial prefrontal cortex differently in autistic men versus women." *Elife* 9.
https://doi.org/10.7554/eLife.55684. https://www.ncbi.nlm.nih.gov/pubmed/32746967.
Tran, T. T., C. E. Rolle, A. Gazzaley, and B. Voytek. 2020. "Linked Sources of Neural Noise Contribute to
Age-related Cognitive Decline." *J Cogn Neurosci* 32 (9): 1813-1822.
https://doi.org/10.1162/jocn_a_01584. https://www.ncbi.nlm.nih.gov/pubmed/32427069.
Vaghari, D., R. Bruna, L. E. Hughes, D. Nesbitt, R. Tibon, J. B. Rowe, F. Maestu, and R. N. Henson. 2022.
"A multi-site, multi-participant magnetoencephalography resting-state dataset to study
dementia: The BioFIND dataset." *Neuroimage* 258: 119344.
https://doi.org/10.1016/j.neuroimage.2022.119344.
https://www.ncbi.nlm.nih.gov/pubmed/35660461.
Vaghari, D., E. Kabir, and R. N. Henson. 2022. "Late combination shows that MEG adds to MRI in
classifying MCI versus controls." *Neuroimage* 252: 119054.
https://doi.org/10.1016/j.neuroimage.2022.119054.
https://www.ncbi.nlm.nih.gov/pubmed/35247546.
van der Kant, R., L. S. B. Goldstein, and R. Ossenkoppele. 2020. "Amyloid-β-independent regulators of
tau pathology in Alzheimer disease." *Nat Rev Neurosci* 21 (1): 21-35.
https://doi.org/10.1038/s41583-019-0240-3.
https://www.ncbi.nlm.nih.gov/pubmed/31780819.
van Heumen, S., J. T. Moreau, E. Simard-Tremblay, S. Albrecht, R. W. Dudley, and S. Baillet. 2021. "Case
Report: Aperiodic Fluctuations of Neural Activity in the Ictal MEG of a Child With Drug-
Resistant Fronto-Temporal Epilepsy." *Front Hum Neurosci* 15: 646426.
https://doi.org/10.3389/fnhum.2021.646426.
https://www.ncbi.nlm.nih.gov/pubmed/33746727.
van Nifterick, A. M., A. A. Gouw, R. E. van Kesteren, P. Scheltens, C. J. Stam, and W. de Haan. 2022. "A
multiscale brain network model links Alzheimer's disease-mediated neuronal hyperactivity to
large-scale oscillatory slowing." *Alzheimers Res Ther* 14 (1): 101.
https://doi.org/10.1186/s13195-022-01041-4.
https://www.ncbi.nlm.nih.gov/pubmed/35879779.
Varley, T. F., O. Sporns, A. Puce, and J. Beggs. 2020. "Differential effects of propofol and ketamine on
critical brain dynamics." *PLoS Comput Biol* 16 (12): e1008418.
https://doi.org/10.1371/journal.pcbi.1008418.
https://www.ncbi.nlm.nih.gov/pubmed/33347455.
Verret, L., E. O. Mann, G. B. Hang, A. M. Barth, I. Cobos, K. Ho, N. Devidze, E. Masliah, A. C. Kreitzer, I.
Mody, L. Mucke, and J. J. Palop. 2012. "Inhibitory interneuron deficit links altered network
activity and cognitive dysfunction in Alzheimer model." *Cell* 149 (3): 708-21.
https://doi.org/10.1016/j.cell.2012.02.046.
https://www.ncbi.nlm.nih.gov/pubmed/22541439.
Vossel, K. A., A. J. Beagle, G. D. Rabinovici, H. Shu, S. E. Lee, G. Naasan, M. Hegde, S. B. Cornes, M. L.
Henry, A. B. Nelson, W. W. Seeley, M. D. Geschwind, M. L. Gorno-Tempini, T. Shih, H. E. Kirsch,
P. A. Garcia, B. L. Miller, and L. Mucke. 2013. "Seizures and epileptiform activity in the early
stages of Alzheimer disease." *JAMA Neurol* 70 (9): 1158-66.
https://doi.org/10.1001/jamaneurol.2013.136.
https://www.ncbi.nlm.nih.gov/pubmed/23835471.
Voytek, B., M. A. Kramer, J. Case, K. Q. Lepage, Z. R. Tempesta, R. T. Knight, and A. Gazzaley. 2015.
"Age-Related Changes in 1/f Neural Electrophysiological Noise." *J Neurosci* 35 (38): 13257-65.

https://doi.org/10.1523/JNEUROSCI.2332-14.2015.
https://www.ncbi.nlm.nih.gov/pubmed/26400953.
Wang, R., and P. H. Reddy. 2017. "Role of Glutamate and NMDA Receptors in Alzheimer's Disease." *J*
Alzheimers   Dis   57   (4):   1041-1048.   https://doi.org/10.3233/JAD-160763.
https://www.ncbi.nlm.nih.gov/pubmed/27662322.
Wang, X. J. 1999. "Synaptic basis of cortical persistent activity: the importance of NMDA receptors to
working   memory."   *J   Neurosci*   19   (21):   9587-603.
https://www.ncbi.nlm.nih.gov/pubmed/10531461.
Yang, H., W. L. Shew, R. Roy, and D. Plenz. 2012. "Maximal variability of phase synchrony in cortical
networks   with   neuronal   avalanches."   *J   Neurosci*   32   (3):   1061-72.
https://doi.org/10.1523/JNEUROSCI.2771-11.2012.
https://www.ncbi.nlm.nih.gov/pubmed/22262904.
Zimmermann, J., A. Perry, M. Breakspear, M. Schirner, P. Sachdev, W. Wen, N. A. Kochan, M.
Mapstone, P. Ritter, A. R. McIntosh, and A. Solodkin. 2018. "Differentiation of Alzheimer's
disease based on local and global parameters in personalized Virtual Brain models."
Neuroimage   Clin   19:   240-251.   https://doi.org/10.1016/j.nicl.2018.04.017.
https://www.ncbi.nlm.nih.gov/pubmed/30035018.
Zott, B., M. M. Simon, W. Hong, F. Unger, H. J. Chen-Engerer, M. P. Frosch, B. Sakmann, D. M. Walsh,
and A. Konnerth. 2019. "A vicious cycle of β amyloid-dependent neuronal hyperactivation."
Science   365   (6453):   559-565.   https://doi.org/10.1126/science.aay0198.
https://www.ncbi.nlm.nih.gov/pubmed/31395777.

890